Wells Fargo Upgrades Sutro Biopharma to Overweight, Raises Price Target to $27

Wells Fargo analyst Eva Fortea Verdejo has upgraded Sutro Biopharma (NASDAQ: STRO) from Equal-Weight to Overweight. The price target for the stock has been raised significantly from $8 to $27.